肝细胞癌预后相关细胞分子生物标志物研究进展

doi:10.3760/cma.j.issn.1673422X.2015.05.021

摘要/Abstract

摘要： 肝细胞癌(HCC)的发生发展过程是一个多种基因和细胞、分子以及多条信号通路参与的复杂网络机制。不同水平的生物分子标志物作用与机制也各不相同，但目前仍缺乏对HCC患者预后进行评价的有效分子标志物。研究表明，在HCC的基因表达与调控过程以及细胞周期调节及肿瘤干细胞增殖与分化过程中均有相应的分子标志物参与。其中，p53基因及其相关分子、非编码转录RNA(微小RNA、长链非编码RNA )、细胞周期调节因子和肝癌干细胞表面相关分子与HCC的预后密切相关。

关键词: 癌, 肝细胞/微RNAs/细胞周期/肿瘤干细胞

Abstract: The occurence and progress of hepatocellular carcinoma (HCC) is a complex network interaction process connected by multiple signaling pathways involving genes, cells and various active molecules. The effects and functions of biological molecular markers also vary among different pathways. Moreover, whether the molecular markers have prediction effects for the prognosis of HCC remains unclear, and studies investing this issue are still insufficient. The current studies reveal that molecular markers involves in multiple pathways including gene expression, gene regulation, cell cycle regulation, cancer stem cell proliferation and differentiation. These processes are intimately associated with the occurrence and prognosis of HCC. The relevant gene or molecular that may indicate the prognosis of HCC includes p53 gene, long noncoding RNA, cell cycle regulators, liver cancer stem cell surfaceassociated molecules, etc.

李保国, 郭志. 肝细胞癌预后相关细胞分子生物标志物研究进展[J]. 国际肿瘤学杂志, 2015, 42(5): 395-398.

LI Bao-Guo, GUO Zhi. Molecular biomarkers related prognosis in hepatocellular carcinoma[J]. Journal of International Oncology, 2015, 42(5): 395-398.

参考文献

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin， 2011, 61(2): 6990. ［2］ Minguez B, Lachenmayer A. Diagnostic and prognostic molecular markers in hepatocellular carcinoma［J］. Dis Markers,2011, 31(3):181190. ［3］ Singhal A, Jayaraman M, Dhanasekaran DN, et al. Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence［J］. Crit Rev Oncol Hematol, 2012, 82(2): 116140. ［4］ Zhao Y, Jian W, Gao W, et al. RNAi silencing of cMyc inhibits cell migration, invasion, and proliferation in HepG2 human hepatocellular carcinoma cell line: cMyc silencing in hepatocellular carcinoma cell［J］. Cancer Cell Int, 2013, 13(1)： 23. ［5］ Kotsafti A, Farinati F, Cardin R, et al. Autophagy and apoptosisrelated genes in chronic liver disease and hepatocellular carcinoma［J］. BMC Gastroenterol, 2012, 12： 118111. ［6］ Yang Y, Xia T, Li N, et al. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virusrelated hepatocellular carcinoma［J］. Protein Cell, 2013, 4(1)： 7181. ［7］ Dong L, Liu Y, Qiu Y, et al. Identification of Pirh2E and Pirh2F, two additional novel isoforms of Pirh2 ubiquitin ligase from human hepatocellular liver carcinoma cell line［J］. Biomed Mater Eng, 2012, 22(13)： 8995. ［8］ Zhang Y, Guo X, Xiong L, et al. MicroRNA101 suppresses SOX9dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma［J］. FEBS Lett, 2012, 586(24)： 43624370. ［9］ Guo X, Xiong L, Sun T, et al. Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma［J］. Diagn Pathol, 2012, 7： 44. ［10］ Zhang D, Cao L, Li Y, et al. Expression of gliomaassociated oncogene 2 (Gli 2) is correlated with poor prognosis in patients with hepatocellular carcinoma undergoing hepatectomy［J］. World J Surg Oncol, 2013, 11： 25. ［11］ Xi SY, Lu JB, Chen JW, et al. The "stonelike" pattern of LC3A expression and its clinicopathologic significance in hepatocellular carcinoma［J］. Biochem Biophys Res Commun, 2013, 431(4)： 760766. ［12］ He H, Wu G, Li W, et al. CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis［J］. Diagn Mol Pathol, 2012, 21(3)： 143149. ［13］ Melo SA, Sugimoto H, O'Connell JT , et al.. Cancer exosomes perform cellindependent microRNA biogenesis and promote tumorigenesis［J］. Cancer Cell, 2014, 26(5)： 707721. ［14］ Cheng CJ, Bahal R, Babar IA, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment ［J］. Nature, 2015, 518(7537): 107110. ［15］ Dai X, Zhang W, Zhang H, et al. Modulation of HBV replication by microRNA15b through targeting hepatocyte nuclear factor 1α［J］. Nucleic Acids Res, 2014, 42(10)： 65786590. ［16］ Braconi C, Kogure T, Valeri N, et al. microRNA29 can regulate expression of the long noncoding RNA gene MEG3 in hepatocellular cancer ［J］. Oncogene, 2011, 30(47)： 47504756. ［17］ Shi C, Xu X. MicroRNA22 is downregulated in hepatitis B virusrelated hepatocellular carcinoma［J］. Biomed Pharmacother, 2013, 67(5)： 375380. ［18］ Zhu HT, Dong QZ, Sheng YY, et al. MicroRNA29a5p is a novel predictor for early recurrence of hepatitis B virusrelated hepatocellular carcinoma after surgical resection［J］. PLoS One, 2012, 7(12)： e52393. ［19］ Dohi O, Yasui K, Gen Y, et al. Epigenetic silencing of miR335 and its host gene MEST in hepatocellular carcinoma［J］. Int J Oncol, 2013, 42(2)： 411418. ［20］ Gu H, Guo X, Zou L, et al. Upregulation of microRNA372 associates with tumor progression and prognosis in hepatocellular carcinoma［J］. Mol Cell Biochem, 2013, 375(12)： 2330. ［21］ ChangHao Tsao S, Behren A, Cebon J, et al. The role of circulating microRNA in hepatocellular carcinoma［J］. Front Biosci (Landmark Ed). 2015， 20： 78104. ［22］ Fornari F, Milazzo M, Galassi M, et al. p53/mdm2 feedback loop sustains miR221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma［J］. Mol Cancer Res， 2014 ， 12(2)： 203216. ［23］ Kitagawa M, Kitagawa K, Kotake Y, et al. Cell cycle regulation by long noncoding RNAs［J］. Cell Mol Life Sci， 2013， 70(24)： 47854794. ［24］ Yang Z, Zhou L, Wu LM, et al. Overexpression of long noncoding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation［J］. Ann Surg Oncol, 2011, 18(5)： 12431250. ［25］ Lai MC, Yang Z, Zhou L, et al. Long noncoding RNA MALAT1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation［J］. Med Oncol, 2012, 29(3)： 18101816. ［26］ Yang F, Zhang L, Huo XS, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans［J］. Hepatology, 2011, 54(5)： 16791689. ［27］ Li Y, Yang XH, Fang SJ, et al.. HOXA7 stimulates human hepatocellular carcinoma proliferation through cyclin E1/CDK2 ［J］ . Oncol Rep， 2015， 33(2)： 990996. ［28］ Lu JW, Lin YM, Chang JG, et al. Clinical implications of deregulated CDK4 and Cyclin D1 expression in patients with human hepatocellular carcinoma［J］. Med Oncol, 2013, 30(1)： 379. ［29］ Jia Q, Zhang X, Deng T, et al. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells［J］. Cell Reprogram, 2013, 15(2)： 143150. ［30］ GrosseGehling P, Fargeas CA, Dittfeld C, et al. CD133 as a biomarker for putative cancer stem cells in solid tumours： limitations, problems and challenges［J］. J Pathol, 2013, 229(3)： 355378. ［31］ Ezzeldin M, BorregoDiaz E, Taha M, et al. RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC)［J］. Mol Oncol, 2014, 8(5)： 10431053. ［32］ Tang KH, Ma S, Lee TK, et al. CD133(+) liver tumorinitiating cells promote tumor angiogenesis, growth, and selfrenewal through neurotensin/interleukin8/CXCL1 signaling［J］. Hepatology, 2012, 55(3)： 807820. ［33］ Ma YC, Yang JY, Yan LN. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients： a metaanalysis［J］. Eur J Gastroenterol Hepatol, 2013, 25(9)： 10071016. ［34］ Shan YF, Huang YL, Xie YK, et al. Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and alphafetoprotein expression status［J］. Med Oncol, 2011, 28(4)： 10121016. ［35］ Guo Z, Li LQ, Jiang JH, et al. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma［J］. World J Gastroenterol, 2014, 20(8)： 20982106. ［36］ Yamashita T, Honda M, Nakamoto Y, et al. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma［J］. Hepatology, 2013, 57(4)： 14841497. ［37］ Mima K, Okabe H, Ishimoto T, et al. CD44s regulates the TGFbetamediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma［J］. Cancer Res, 2012, 72(13)： 34143423. ［38］ Oikawa T, Kamiya A, Zeniya M, et al. Sallike protein 4 (SALL4), a stem cell biomarker in liver cancers［J］. Hepatology, 2013, 57(4)： 14691483.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[6]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[7]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[8]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[9]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[10]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[11]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[12]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[13]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[14]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[15]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.